TwinBeech Capital’s Karyopharm Therapeutics KPTI Stock Holding History

TwinBeech Capital’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,066	Closed	-$168K	–	558
2021 Q1	$168K	Buy	+1,066	New	+$225K	0.02%	428
2020 Q4	–	Sell	-1,942	Closed	-$425K	–	528
2020 Q3	$425K	Buy	+1,942	New	+$475K	0.09%	293

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

DMPV

Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

TwinBeech Capital's KPTI Position: Q2 2021 in Review

TwinBeech Capital sold out of Karyopharm Therapeutics (KPTI) in Q2 2021, closing a stake of 1,066 shares — an estimated $168K sold.

TwinBeech Capital first reported a position in KPTI in Q3 2020 and held it in 2 quarters. The position peaked at $425K in Q3 2020. 153 funds tracked by Wall St. Rank hold KPTI as of Q2 2021.

TwinBeech Capital reported no remaining Karyopharm Therapeutics position as of Q2 2021 after selling out during the quarter.
TwinBeech Capital sold 1,066 Karyopharm Therapeutics shares in Q2 2021, an estimated $168K.
TwinBeech Capital first reported a position in Karyopharm Therapeutics in Q3 2020 and held it in 2 quarters.
TwinBeech Capital's Karyopharm Therapeutics position peaked at $425K in Q3 2020.
153 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2021.

Based on TwinBeech Capital's 13F filing for Q2 2021, filed 16 Aug 2021.